Lilly states that Retatrutide is not yet available for public use, remains in Phase 3 clinical trials, and that public launch depends on the completion of those trials plus regulatory approval, with additional Phase 3 results anticipated in 2026
Signs include: Hives or widespread rash beyond the injection site Swelling of face, lips, tongue, or throat Difficulty breathing or wheezing Rapid heartbeat Feeling faint or losing consciousness These symptoms require immediate medical attention
14 months: Weight regain slows and plateaus at approximately 75% of the original weight loss
Pfizer Provides Update on GLP-1-RA clinical development program for adults with obesity and type 2 diabetes mellitus | Pfizer
DualSource Vitamin C for Maximum Effectiveness This supplement combines ascorbate Vitamin C with Rose Hips, a natural plant source of Vitamin C, to improve absorption and stability, helping the body use Vitamin C more efficiently for skin support
Guillermo Castillo, Board Certified Family Medicine, oversees all GLP-1 programs